Fresenius company profile

FRE · Xetra · EUR

Compare Fresenius
€53.75Change from previous close: −0.20%Absolute change: −€0.11

Close · November 17, 2026

Company profile

Fresenius has 179,493 employees and is headquartered in Bad Homburg vor der Höhe, Germany.

Hospitals, clinics, physicians and patients with chronic or critical illnesses in North America, Europe, Asia-Pacific, Latin America and Africa are the customers of Fresenius SE & Co. KGaA. Its Fresenius Kabi unit supplies biopharmaceuticals, clinical nutrition, biosimilars, generic injectable drugs, IV fluids, infusion pumps, apheresis machines and cell therapy devices. The Fresenius Helios unit runs hospitals, medical care centers, occupational health and outpatient centers and provides medical diagnostics. The company is also working with SAP SE and Avelios Medical GmbH on a cloud-native, modular hospital information system with AI integration.

In the fiscal year ended December 2025, revenue reached EUR 22.9 billion, up 4.2% from the previous year, and net income was EUR 1.3 billion. The group employs 179,493 people. Founded in 1912, it is headquartered in Bad Homburg vor der Höhe, Germany, and adopted its current name in January 2011.

Company facts

Industry
Medical Care Facilities
Country
Germany
Headquarters
Else-Kröner-Straße 1, 61352, Bad Homburg vor der Höhe
Employees
179,493
Chief executive
Michael Sen
Founded
1912
Fiscal year
January - December
Listing
FRE · Xetra
Indices
DAX
Currency
EUR
ISIN
DE000FRE5EN2

Fresenius and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
FreseniusFREGermany$29.53B179,4939.8%17.2
Fresenius Medical CareFMEGermany$11.77B106,29110.3%12.1
MedicoverMCOV.BSweden$3.88B49,0007.4%38.5
Spire Healthcare GroupSPIUnited Kingdom$1.31B17,8006.2%—
TerveystaloTTALOFinland$848.65M8,1118.9%13.5
Tenet HealthcareTHCUnited States$23.2B77,00019.1%8.53

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Fresenius with its competitors